PropThink: OPTR Fighting Weak Dificid Trends With Price Reduction, Estimates Going Down

[ACN Newswire] – By David MoskowitzOptimer Pharmaceuticals (NASDAQ:OPTR) is hosting its Analyst Day in NYC this morning and is detailing its new strategy, which includes lowering the price for lead growth driver, Dificid, … more

View todays social media effects on OPTR

View the latest stocks trending across Twitter. Click to view dashboard